Journal article
MP37-01 A COST-UTILITY ANALYSIS OF ENFORTUMAB VEDOTIN AND PEMBROLIZUMAB VERSUS NIVOLUMAB PLUS GEMCITABINE-CISPLATIN IN ADVANCED UROTHELIAL CARCINOMA
Authors
Cheung DC; Bernardino R; May JA; Papasideris M; Bremner KE; Fleshner NE; Lalani A-K; Ong M; Wong WL; Wallis C
Journal
Journal of Urology, Vol. 213, No. 5S,
Publisher
Wolters Kluwer
Publication Date
May 1, 2025
DOI
10.1097/01.ju.0001110176.07507.51.01
ISSN
0021-0005